[alephnerd]

That's why the major Indian generics companies like Cipla have signed IP and branding exclusivity deals with Lilly and Novo so that they can continue to synthesize generic GLPs but Lilly and Novo can now export those to the US - it allows IP holders in the US to further enhancing margins while allowing Indian generics manufacturers to climb up the value chain thanks to transferred IP and knowhow.